Literature DB >> 12051396

IL-6 promoter polymorphism at position -174 modulates the phenotypic expression of polymyalgia rheumatica in biopsy-proven giant cell arteritis.

M A Gonzalez-Gay1, A H Hajeer, A Dababneh, C Garcia-Porrua, D L Mattey, M M Amoli, W Thomson, W E R Ollier.   

Abstract

OBJECTIVES: Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are related diseases in which diverse genetic and environmental factors are implicated. Both GCA and PMR are characterized by an intense acute phase reaction. In these sYndromes the increased production of IL-6 has been observed. To investigate further the genetic influence of IL-6 in GCA and PMR we have examined the IL-6 promoter polymorphism (G to C) at position -174 in the 5' region in a series of patients from Northwest Spain diagnosed with GCA and/or PMR.
METHODS: Sixtxy-two biopsy-proven GCA patients (30 of them with associated PMR) and 84 patients with isolated PMR were studied. Patients and ethnically matched controls (n = 124) were from the Lugo region (Galicia, Northwest Spain). Patients and controls were genotyped for HLA-DRB1 and IL-6 polymorphism at position -174 by molecular methods.
RESULTS: IL-6-174 allele C was marginally increased infrequency in GCA patients with PMR manifestations compared with isolated GCA (Pcorr 0.06; OR = 2.3). The increase in the frequency of the CC genotype in GCA patients with PMR versus those with isolated GCA was statistically significant (Pcorr 0.02). The increased frequency of allele C in GCA patients with PMR was more commonly observed in HLA-DRBI *04 negative patients. However, this polymorphism was not associated with a higher risk of ischemic events in GCA or with relapses in PMR.
CONCLUSION: Allele C at position -174 in the 5' promoter region of the IL-6 gene may be associated with PMR in biopsy-proven GCA patients not carrying HLA-DRBI *04 alleles.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12051396

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  6 in total

Review 1.  Cytokine gene considerations in giant cell arteritis: IL10 promoter polymorphisms and a review of the literature.

Authors:  Lorena Alvarez-Rodriguez; Marcos Lopez-Hoyos; Eugenio Carrasco-Marín; Gaurav Tripathi; Pedro Muñoz Cacho; Cristina Mata; Jaime Calvo-Alen; Maite Garcia-Unzueta; Elena Aurrecoechea; Victor Manuel Martinez-Taboada
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

Review 2.  Clinical features of polymyalgia rheumatica and giant cell arteritis.

Authors:  Carlo Salvarani; Nicolò Pipitone; Annibale Versari; Gene G Hunder
Journal:  Nat Rev Rheumatol       Date:  2012-07-24       Impact factor: 20.543

3.  Association between rs1800795 polymorphisms in the interleukin-6 gene and vasculitis: A meta-analysis.

Authors:  Jae Hyun Jung; Hongdeok Seok; Sung Jae Choi; Gwan Gyu Song; Youngjin Han
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

4.  HLA-DRB1 and -DQB1 alleles and gene polymorphisms of selected cytokines in systemic lupus erythematosus.

Authors:  Antoni Hrycek; Urszula Siekiera; Paweł Cieślik; Witold Szkróbka
Journal:  Rheumatol Int       Date:  2004-09-21       Impact factor: 2.631

5.  Association between IL-18 gene polymorphisms and biopsy-proven giant cell arteritis.

Authors:  Rogelio J Palomino-Morales; Tomas R Vazquez-Rodriguez; Orlando Torres; Inmaculada C Morado; Santos Castañeda; Jose A Miranda-Filloy; Jose L Callejas-Rubio; Benjamin Fernandez-Gutierrez; Miguel A Gonzalez-Gay; Javier Martin
Journal:  Arthritis Res Ther       Date:  2010-03-23       Impact factor: 5.156

6.  Interleukin-6: a promising target for the treatment of polymyalgia rheumatica or giant cell arteritis?

Authors:  Éric Toussirot; Alexis Régent; Valérie Devauchelle-Pensec; Alain Saraux; Xavier Puéchal
Journal:  RMD Open       Date:  2016-08-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.